SCHEMBL2872219

SCHEMBL2872219

COc1cc(-c2nc3c(C#N)c[nH]n3c2Nc2cccc(C#N)c2)cc(OC)c1OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.49
▸ SLK Q9H2G2 2/20 0.47
▸ STK10 O94804 1/20 0.46
▸ TP53 P04637 2/20 0.46
▸ ADORA2A P29274 1/20 0.44
▸ ADORA1 P30542 1/20 0.44
▸ BRAF P15056 1/20 0.43
▸ EGFR P00533 1/20 0.43
▸ ERBB2 P04626 1/20 0.43
▸ ABCG2 Q9UNQ0 2/20 0.42
▸ PTK2 Q05397 1/20 0.42
▸ KDM5A P29375 1/20 0.40
▸ DCUN1D1 Q96GG9 1/20 0.40
▸ TUBB4A P04350 1/20 0.40
▸ TUBB P07437 1/20 0.40
▸ TUBA3C P0DPH7 1/20 0.40
▸ TUBA1B P68363 1/20 0.40
▸ TUBA4A P68366 1/20 0.40
▸ TUBB4B P68371 1/20 0.40
▸ TUBB3 Q13509 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2126838 0.88 MAPT (0.47) MAPTTP53ADORA2AADORA1EGFR
SCHEMBL2123865 0.87 KDM5A (0.50) MAPTTP53ADORA2AADORA1EGFR
SCHEMBL2123837 0.83 MAPT (0.52) MAPTTP53ADORA1KDM5A
SCHEMBL2124994 0.83 MAPT (0.48) MAPTTP53KDM5A
SCHEMBL2124185 0.82 KDM5A (0.50) MAPTTP53KDM5A
SCHEMBL2125095 0.82 MAPT (0.48) MAPTTP53ADORA2AADORA1KDM5A
SCHEMBL2124751 0.82 MAPT (0.46) MAPTTP53KDM5A
SCHEMBL2125641 0.82 MAPT (0.48) MAPTTP53ADORA2AADORA1EGFR
SCHEMBL2123116 0.81 KDM5A (0.47) MAPTTP53ADORA2AADORA1PTK2
SCHEMBL2122035 0.81 KDM5A (0.54) MAPTSLKSTK10TP53ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2443123-B1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) RIGEL PHARMACEUTICALS INC (US) 2017-04-05 — — EP disclosed
US-8377945-B2 Small molecule inhibitors of spleen tyrosine kinase (SYK) RIGEL PHARMACEUTICALS INC. (US) 2013-02-19 — — US disclosed
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) MIDCAP FINANCIAL TRUST 2010-12-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100316649-A1 SMALL MOLECULE INHIBITORS OF SPLEEN TYROSINE KINASE (SYK) SYK, BTK, LCK MAPT 4045/4885SLK 243/4885STK10 201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback